Abbott Laboratories (ABT)
After hours:
| Previous Close | 105.92 |
| Open | 106.11 |
| Bid | 105.89 x 1200 |
| Ask | 107.21 x 1400 |
| Day's Range | 105.47 - 106.64 |
| 52 Week Range | 89.67 - 121.64 |
| Volume | |
| Avg. Volume | 5,638,783 |
| Market Cap | 184.227B |
| Beta (5Y Monthly) | 0.74 |
| PE Ratio (TTM) | 32.99 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.20 (2.08%) |
| Ex-Dividend Date | Apr 12, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
- ACCESSWIRE
It's Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...
- PR Newswire
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
